Partners will leverage Likarda’s Core-Shell Spherification® platform for slow and steady release of hormones such as testosterone and estradiol with a single, infrequent injection Kansas City, MO and Reno, NV, December 11, 2024 – Likarda, a leading biotech company...

Kansas City, MO and FRANKLIN, MA, Jun 3, 2024 – Likarda, Inc., leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, and Cold Chain Technologies, LLC (CCT), a global...

Kansas City, USA, April 17, 2024 – Likarda, a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, today announces the appointment of Shelly Adams as Chief Commercial...

Likarda’s scientists recently published a paper in the journal, Bioengineeing, that demonstrates the improved outcomes when stem cells are injected into the joint with ViscoCell™, a hydrogel formulated specifically for arthritic joints.   Osteoarthritis (OA) is an...

Kansas City, MO, October 10, 2023 – Likarda, a leader in cell therapy encapsulation for delivery and Evia Bio, a life sciences innovation company that develops non-DMSO cryopreservation solutions, announced today a strategic partnership to deliver better and safer...

Cambridge, Massachusetts, September 13, 2023 – Likarda, LLC, a pioneering cell therapy company, is at the forefront of creating advanced delivery systems that enhance the efficacy of cell therapies. Central to their innovative approach is the Core-Shell...

Likarda’s Custom Hydrogel Encapsulant to be Used as Cell Therapy Delivery System to Treat Equine Lameness Cambridge, Massachusetts, February 17, 2022 – Likarda, LLC is a cell therapy company developing innovative delivery systems to optimize cell therapies. Their...